AAV-DJ SP-B Luciferase particles transduce firefly (Photinus pyralis) luciferase under the control of a SP-B (Surfactant protein B) promoter that drives luciferase reporter expression mainly in epithelial lung cells.
●
Product Data Gallery
Purified AAV-DJ SP-B- Luciferase particles.
Luciferase activity in HEK293 cells transduced with AAV-DJ SP-B-Luciferase particles.
Two vials (50 µl x 2) of AAV at a titer ≥1 x 1012 vector genomes/ml. The titer is determined by qPCR and varies with each lot; the exact value will be provided with each shipment.
Purification
The purity of the AAV particles was confirmed to be greater than 90% by staining with One-Step Lumitein™ UV Protein Gel Stain (Biotium, 21005-1L). The purity varies with each lot; the exact value will be provided with each shipment
Formulation
AAV was produced in HEK293-AAV cells and is supplied in PBS-MK (PBS Magnesium-Potassium) buffer containing 0.01% Pluronic F68. Virus particles can be packaged in custom formulations by special request, for an additional fee.
Background
Adeno-Associated Virus-DJ (AAV-DJ) is a synthetic serotype made from eight different wild-type AAV serotypes (AAV2, 4, 5, 8, 9, avian, bovine, and goat AAV) using DNA shuffling. These modifications allow the AAV-DJ serotype to exhibit improved transduction efficiency in vitro and in vivo and infect a broader range of cell types compared to the wild-type serotypes.
Surfactant protein B (SP-B) is a developmentally and hormonally regulated lung protein that is required for normal surfactant function. SP-B is selectively expressed in bronchiolar and alveolar epithelial cells of the lung and it is found to be associated with lipids. Surfactant is a mixture of proteins and lipids that allows proper inflation of the lung and breathing. Deficiency in SP-B results in lethality at birth. The human SP-B promoter fragment directs epitheliallung-cell specific transgene expression.
Storage/Stability
AAV is shipped with dry ice. For long-term storage, it is recommended to store AAV at -80°C for up to 12 months from date of receipt. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle
Applications
Positive control in the transduction of lung epithelial cells.
Optimization of transduction assays and tracking of transgene expression over time.
Shipping Temperature
-80°C
Notes
The AAV-DJ viruses are covered under several patents, including U.S. Patent Nos. 7,588,772, 8,067,014, 8,574,583, and 8,906,387, as well as corresponding foreign patents applications and patent rights. AAV-DJ is used under a license agreement.
Biosafety Recombinant AAV is inherently replication-deficient and not known to cause any human diseases. Additionally, following transduction, AAV vectors exist episomally and do not integrate into or disrupt the host cell’s genome. AAV requires the use of a Biosafety Level 1 facility. BPS Bioscience recommends following all local, federal, state, and institutional regulations and using all appropriate safety precautions